Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

NCT ID: NCT03240016

Last Updated: 2025-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-08
• Study Completion Date: 2023-06-23

Brief Summary

This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer.

Each cycle last 21-days. All subjects will receive pembrolizumab via IV on day 1, and abraxane via IV on Day 1 and Day 8 of each cycle. Subjects may continue to receive the study regimen until they experience disease progression or unacceptable toxicity.

Conditions

Urothelial Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pembrolizumab and Abraxane

Pembrolizumab 200mg IV D1 Abraxane 100mg/m\^2 IV D1 and D8 21 Day Cycles

Group Type: EXPERIMENTAL

Pembrolizumab

Intervention Type: DRUG

200mg IV D1

Abraxane

Intervention Type: DRUG

100mg/m\^2 D1 and D8

Interventions

Pembrolizumab

200mg IV D1

Intervention Type: DRUG

Abraxane

100mg/m\^2 D1 and D8

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with recurrent unresectable locally advanced or metastatic urothelial carcinoma (aka transitional cell carcinoma).
• Patients may be either cisplatin-ineligible or platinum-refractory.
• Histological or cytologically proven urothelial carcinoma.
• Have measurable disease based on RECIST 1.1
• Has urothelial cancer that is not suitable for local therapy administered with curative intent if not already administered.
• Must have recovered (i.e., AE <= Grade 1 or stable) from AEs due to a previously administered agent.
• ECOG Performance Status of 0, 1 or 2. (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.)
• Prior neoadjuvant or adjuvant systemic therapy or local intravesical chemotherapy or immunotherapy is permitted.
• Adequate organ and marrow function
• Women of child-bearing potential must either commit to true abstinence or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting IP therapy, and while on study medication or for a longer period if required by local regulations following the last dose of IP; and have a negative serum pregnancy test result at screening
• Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following drug discontinuation, even if he has undergone a successful vasectomy.
• Patients must have < Grade 2 pre-existing peripheral neuropathy
• Be ≥18 years of age as of date of signing informed consent
• Voluntarily agree to participate by providing written informed consent/assent for the trial

Exclusion Criteria

• Prior exposure to immune-mediated therapy
• History of allogenic organ transplantation that requires ongoing use of immunosuppressive agents is NOT permitted
• Active or prior documented autoimmune or inflammatory disorders are NOT permitted
• Current or prior use of immunosuppressive medication(s) within 14 days before study treatment is NOT permitted.
• Brain metastases or spinal cord compression are NOT permitted unless they have been treated with the patient's condition being stable clinically and radiologically for 28 calendar days and off steroids for at least 14 days prior to the start of study treatment.
• Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permitted.
• Receipt of live attenuated vaccine within 30 days prior to the first study treatment is NOT permitted.
• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 28 calendar days of the first dose of treatment.
• CTCAE Grade > 1 peripheral neuropathy is NOT permitted
• If subjects received major surgery they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
• Has a known additional malignancy that is progressing or requires active treatment
• Has a history of severe hypersensitivity reaction to nab-paclitaxel or anti-PD1/PDL1
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Pregnancies:

1. Females: nab-paclitaxel can cause harm to an unborn child if given to a pregnant woman. Females may not take part in this study if pregnant or breast-feeding for 6 months after last dose of study drug.

2. Males: Male subjects should avoid fathering a child while receiving study medication and for 6 months after the last dose of study medication. Males must agree to complete abstinence from heterosexual contact or use a condom during sexual contact with a female of child bearing potential while receiving study medication and within 6 months after last dose of study medication.

3. Subjects (both males and female) should practice effective contraception during study and for 6 months after the last dose of study medication (Section 3.1.8 i, ii).

• Patients with biliary obstruction or biliary stent are excluded.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Michigan Rogel Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ajjai Alva, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Michigan Rogel Cancer Center

Locations

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Countries

United States

References

Tsung I, Green E, Palmbos P, Sloan Z, Reichert ZR, Vaishampayan U, Smith DC, Caram MEV, Yentz S, Daignault-Newton S, Hurley L, Nguyen CB, Kraft S, Alva A. A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer. J Urol. 2023 Jan;209(1):121-130. doi: 10.1097/JU.0000000000002969. Epub 2022 Nov 1.

Reference Type: DERIVED

PMID: 36317715 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

HUM00135166

Identifier Type: OTHER

Identifier Source: secondary_id

UMCC 2017.077

Identifier Type: -

Identifier Source: org_study_id